1,2,3,4-tetrahydro-9h-pyrido[3,4-b]indole trpv1 antagonists and their applications

A 4-b, antagonist technology, applied in anti-inflammatory agents, non-central analgesics, medical preparations containing active ingredients, etc., can solve problems such as obvious side effects and inability to be effectively controlled

Active Publication Date: 2021-05-14
HENAN UNIVERSITY
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although these drugs have good clinical effects, their side effects are also obvious, such as the addiction of opioids, the gastrointestinal side effects of non-steroidal anti-inflammatory drugs, etc.
In addition, a significant number of pain types such as chronic and neuropathic pain cannot be effectively controlled with existing medications

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • 1,2,3,4-tetrahydro-9h-pyrido[3,4-b]indole trpv1 antagonists and their applications
  • 1,2,3,4-tetrahydro-9h-pyrido[3,4-b]indole trpv1 antagonists and their applications
  • 1,2,3,4-tetrahydro-9h-pyrido[3,4-b]indole trpv1 antagonists and their applications

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] 2-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-2,3,4,9-tetrahydro-1H-pyrido[3 , Preparation of 4-b]indole (1)

[0045]

[0046] (a) Preparation of 1-azido-4-chlorobenzene

[0047] Under ice-cooling, p-chloroaniline (1.27g, 10mmol) was dissolved in 6mol / L HCl (10ml) in a round bottom flask, and NaNO 2 (0.69g, 10mmol) was dissolved in 25ml of water and added dropwise to the above reaction system. The mixture was stirred for 20 min, NaN 3 (1.95g, 30mmol) was dissolved in 40ml of water and added dropwise. Stir at room temperature for 2-4h, extract with ethyl acetate (30ml×2), combine the organic phases and wash with water (30ml×3), evaporate the solvent under reduced pressure to obtain 1-azido-4-chlorobenzene;

[0048] (b) Preparation of 2-(prop-2-yn-1-yl)-2,3,4,9-tetrahydro-9H-pyrido[3,4-b]indole

[0049] 1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indole (1.72g, 10mmol), K 2 CO 3 (0.69g, 0.5mmol) was dissolved in acetone (10ml) to obtain solution A. Propylene brom...

Embodiment 2

[0054] 2-((1-(isoquinolin-5-yl)-1H-1,2,3-triazol-4-yl)methyl)-2,3,4,9-tetrahydro-1H-pyrido Preparation of [3,4-b]indole (2)

[0055]

[0056] Referring to the preparation method in Example 1, wherein p-chloroaniline was replaced with pentaaminoisoquinoline, compound 2 was obtained as a brownish yellow solid with a yield of 87%. The experimental data are as follows:

[0057] C 23 h 20 N 6 , yield 87%, brown yellow solid, m.p=147.2-149.6℃; 1 H NMR (CDCl 3 ,400MHz): δppm 9.33(s,1H,NH),8.70(s,1H,C=CH),8.54(s,1H,Ar-H),8.09(d,1H,J=12.0Hz,Ar-H ),7.91(s,1H,Ar-H),7.73-7.63(m,2H,Ar-H),7.54(d,1H,J=8.0Hz,Ar-H),7.44(d,1H,J= 12.0Hz, Ar-H), 7.24(t, 1H, J=8.0Hz, Ar-H), 7.10-7.01(m, 2H, Ar-H), 4.05(s, 2H, CH 2 ),3.79(s,2H,CH 2 ),3.02(t,2H,J=6.0Hz,CH 2 ),2.86(t,2H,J=6.0Hz,CH 2 ); HRMSm / z:[M+H] + 381.1819 (calcd. 381.1822).

Embodiment 3

[0059] 2-((1-(2-chlorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-2,3,4,9-tetrahydro-1H-pyrido[3 , Preparation of 4-b]indole (3)

[0060]

[0061] Referring to the preparation method in Example 1, wherein o-chloroaniline was used instead of p-chloroaniline, light yellow solid compound 3 was obtained with a yield of 91.6%. The experimental data are as follows:

[0062] C 20 h 18 ClN 5 , yield 91.6%, pale yellow solid, m.p=143.6-145.0℃; 1 H NMR (DMSO, 400MHz): δppm 10.62(s, 1H, NH), 8.42(s, 1H, C=CH), 7.68(d, 1H, J=8.0Hz, Ar-H), 7.62(d, 1H ,J=12.0Hz,Ar-H),7.52(t,2H,J=10.0Hz,Ar-H),7.27(d,1H,J=8.0Hz,Ar-H),7.18(t,1H,J =12.0Hz, Ar-H), 6.94-6.82(m, 2H, Ar-H), 3.87(s, 2H, CH 2 ),3.60(s,2H,CH 2 ),2.79(t,2H,J=8.0Hz,CH 2 ),2.65(t,2H,J=14.0Hz,CH 2 ); HRMS m / z: [M+H] + 364.1319 (calcd. 364.1323).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to 1,2,3,4-tetrahydro-9 H ‑pyrido[3,4‑b]indole TRPV1 antagonist or a pharmaceutically acceptable salt thereof, the general structural formula is as follows: In the formula, R is H, F, Cl, Br, I, CF 3 , methyl, isopropyl, tert-butyl, cyclopropyl, propenyl, ethynyl, hydroxyl, phenoxy, acetyl or phenyl; n is 1, 2 or 3; L is triazolyl, tetra Azolyl, ureido or thiourea; Ar is phenyl, pyridyl, isoquinolyl, quinolinyl or pyrimidinyl. It was found through experiments that: this type of 1,2,3,4-tetrahydro-9 H ‑pyrido[3,4‑b]indole compounds have good TRPV1 inhibitory activity, and the activity of some compounds is much higher than that of TRPV1 receptor antagonist BCTC; compared with BCTC, there is almost no side effect of elevated body temperature. Therefore the general formula 1,2,3,4-tetrahydro-9 of the present invention H ‑pyrido[3,4‑b]indole compounds and their medicinal salts are safe and effective, and have strong analgesic effect.

Description

technical field [0001] The invention belongs to the technical field of medicinal chemistry, and specifically relates to a class of 1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indole TRPV1 antagonists, and a drug containing such compounds as active ingredients Preparations, and their application in the preparation of medicines for the treatment of pain. Background technique [0002] Pain is a common symptom of many diseases, and about 500 million people suffer from various pains every year. At present, the most clinically used analgesics are mainly divided into two categories: one is narcotic analgesics that directly activate opioid receptors, and the other is antipyretic drugs represented by non-steroidal anti-inflammatory drugs (NSAIDs). analgesics. Although these drugs have good clinical effects, their side effects are also obvious, such as the addiction of opioids and the gastrointestinal side effects of non-steroidal anti-inflammatory drugs. In addition, a considerable number ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C07D471/04A61K31/437A61K31/4725A61K31/4439A61K31/4427A61P29/00
Inventor 严琳李金玉聂存斌胡静乔玥
Owner HENAN UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap